Similarly, patients whose tumors had high expression of DVL2 and MAP3K5 were more likely to progress to metastatic disease (Fig. 2G and K; log-rank P = 0.017 and P = 0.000083, respectively). This evidence concerns the gene DVL2 and metastatic neoplasm.